Search Results

You are looking at 1 - 10 of 36 items for :

  • "incretins" x
  • All content x
Clear All

. 2006 3 153 165 Gautier, J. F., Fetita, S., Sobngwi, E. és mtsai: Biological actions of the incretins GIP

Restricted access

. 2006 3 153 165 Drucker, D. J., Nauck, M. A.: The incretin system: glucagon-like peptide-1 receptor

Restricted access

Bloomgarden, Z. T.: Incretin concepts. Diabetes Care, 2010, 33 , e20–e25. Bloomgarden Z. T. Incretin concepts

Restricted access

447 459 Drucker, D. J., Sherman, S. I., Bergenstal, R. M. és mtsa: The safety of incretin-based therapies – review of the scientific evidence. J. Clin. Endocrinol

Restricted access

Meier, J. J., Nauck, M. A.: Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon or impaired β-cell function? Diabetes, 2010, 59 , 1117

Restricted access

. 2006 3 153 165 Drucker, D. J., Nauck, M. A.: The incretin system: glucagon-like peptide-1 receptor

Restricted access

., Picariello, R., Nada, E., et al.: Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study

Restricted access

, 51 (12), 2179–2186. 2 Jermendy, Gy.: Incretin-based therapy in patients with type 2 diabetes mellitus. [Inkretintengelyen ható terápia 2-es típusú

Restricted access

incretin effect in type 2 diabetes just an epi-phenomenon of impaired β-cell function? Diabetes, 2010, 59 , 1117–1125. Nauck M. A. Is the diminished incretin effect in type 2 diabetes

Open access

. S és mtsai: Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care, 2010, 33 , 428–433. Gorelick F. S Incretin

Open access